venerdì, 19 aprile 2024
11 Maggio 2018

Rucaparib FDA Approval Creates Trifecta of Maintenance PARP Inhibitors in Ovarian Cancer

May 8, 2018 – There are now 3 FDA-approved PARP inhibitors in the maintenance setting -niraparib, olaparib, and rucaparib- for patients with ovarian cancer who are in a complete or partial response to platinum-based chemotherapy. The April 2018 approval of rucaparib was based on the results of the phase III ARIEL3 trial, in which 10 patients saw complete responses with rucaparib compared with 1 patient on placebo, leading to an overall response rate of 18%. Results showed that … (leggi tutto)